Phase II Randomized Clinical Trial to Evaluate the Efficacy of the Addition of Polatuzumab Vedotin to Standard Chemotherapy R-DHAP (POLA-R-DHAP) as Induction Pre-transplantation Therapy in Patients With Diffuse Large B-Cell Lymphoma Refractory/Relapsed After First Line Treatment.

Status: Withdrawn prior to enrolment

Phase of Trial: Phase II

Latest Information Update: 23 May 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Polatuzumab vedotin (Primary) ; Cisplatin; Cytarabine; Dexamethasone; Rituximab
Indications B-cell lymphoma; Diffuse large B cell lymphoma; Follicular lymphoma
Focus Therapeutic Use
Acronyms FIL_POLARDHAP

Most Recent Events

20 May 2024 Status changed from discontinued to withdrawn prior to enrolment.
20 May 2024 According to ClinicalTrials.gov: US National Institutes of Health, this trial was withdrawn due to sponsors decision
06 Dec 2023 Planned End Date changed from 1 Oct 2028 to 1 Jan 2029.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight